Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Pick Your Favored kind of sandwich - 2'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'
- 3Comet C/2025 K1 (ATLAS) breaks apart in incredible telescope photos
- 4We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- 5Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- The Best Internet based Courses for Expertise Improvement
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- The Main 15 Applications for Efficiency and Association
- Lucrative Positions in the Advancing Position Market of 2024
- Grasping the Qualifications Among Separation and Dissolution
- Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- The beauty advent calendar boom is here. Sephora kids are all in.
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
